Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics announced that its Compensation Committee approved the grant of non-qualified stock options to purchase 450,000 shares of common stock to two new employees. These inducement grants, given outside the company's 2016 Equity Incentive Plan but adhering to its terms, were approved on June 3, 2024. The stock options' exercise price matches Viridian's closing stock price on the grant date. The grants will vest over four years, with 25% vesting after one year, and the remainder vesting monthly over the next three years, contingent upon continued employment.
- Approval of 450,000 stock options for new employees can attract top talent.
- Stock options vest over four years, potentially increasing employee retention.
- Inducement grants could lead to shareholder dilution.
- Grants made outside the existing equity incentive plan might raise governance concerns.
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606422492/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
What is the significance of the inducement grants announced by Viridian Therapeutics?
When will the Viridian Therapeutics stock options granted on June 3, 2024, vest?
What is the exercise price for the new stock options granted by Viridian Therapeutics?